Radboud University Medical Center: Communicable Diseases trials

The registry lists 17 Communicable Diseases studies with Radboud University Medical Center as lead sponsor. 1 are open to participants now and 2 have results posted.

Phase 1 3Phase 2 1Phase 3 1Phase 4 2No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard StudyRecruitingNCT05652374Phase 4
• Safety and Efficacy of NF135 CPS ImmunizationTerminatedNCT03813108Not applicableResults posted
• Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2CompletedNCT03454048Not applicableResults posted
• Results of Extended Versus Single Dose Antibiotic Prophylaxis In Orthopedic Revision Arthroplasty in Nijmegen.Active, not recruitingNCT06402591Phase 3
• A Controlled Human Pneumococcal Infection Model (PIM) StudyCompletedNCT05361499Not applicable
• Early Postoperative Pain and 30-day Complications Following Major Abdominal Surgery: an Observational StudyCompletedNCT05244655
• Mucosal Immunity Against SARS-CoV-2 Infection in COVID-19 PatientsCompletedNCT04590352
• Pharmacokinetics of Valacyclovir Oral Solution in ChildrenTerminatedNCT04081480Not applicable
• Population Pharmacokinetics of Antibiotics in Critically Ill Children (POPSICLE)Status unknownNCT03248349
• Compliance With Hand Hygiene in Nursing Homes: Go for a Sustainable Effect (CHANGE)CompletedNCT02817282Not applicable
• Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of ValacyclovirCompletedNCT01689285Phase 1
• Palatability Testing of a New Paediatric Formulation of ValacyclovirCompletedNCT01682109Phase 4
• Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variatesCompletedNCT01533558
• Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor RaltegravirCompletedNCT01288417Phase 1
• Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected PatientsCompletedNCT00943540Phase 2
• Pharmacokinetic Study of Posaconazole Boosted FosamprenavirCompletedNCT00817765Phase 1
• Prevention of Renal Failure in Children With Urinary Tract InfectionsCompletedNCT00316043Not applicable